Inflazyme: The best laid plans

Companies with more than one product in their pipelines have an incentive to determine whether such compounds are promising or whether resources should be diverted to back-ups or other programs. However, efforts to make such decisions quickly can meet with frustrating delays.

For example, Inflazyme Pharmaceuticals Ltd. had hoped to conduct a short efficacy study

Read the full 540 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers